Equities

Vectus Biosystems Ltd

VBS:ASX

Vectus Biosystems Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.13
  • Today's Change0.00 / 0.00%
  • Shares traded10.00k
  • 1 Year change-74.00%
  • Beta0.8915
Data delayed at least 20 minutes, as of May 28 2024 06:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.

  • Revenue in AUD (TTM)86.39k
  • Net income in AUD-2.49m
  • Incorporated2005
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hydration Pharmaceuticals Co Ltd15.14m-12.22m3.96m--------0.2618-0.0627-0.06270.0776-0.0021.181.616.60---94.86-79.98-143.75-111.5753.7048.73-80.69-99.531.37-21.481.10--10.3419.2723.61------
Bod Science Ltd3.32m-7.95m4.26m--------1.28-0.0557-0.05570.0235-0.00460.75332.428.05---180.40-94.62-465.66-145.7769.2347.08-239.47-129.480.8319--3.71---34.7023.20-47.10--8.23--
Cambium Bio Ltd-28.22k-366.01k4.60m-----------0.0012-0.0012-0.00009-0.0036-0.039-------50.58-49.44---292.47-------118.34------------60.86------
Zelira Therapeutics Ltd1.62m-36.43m5.33m8.00------3.29-3.23-3.230.148-0.20630.08480.1853.55---193.14-27.71-243.04-28.8182.28---2,278.17-508.480.1488-22.80-----80.95-0.363553.35------
Invex Therapeutics Ltd837.95k-6.01m6.01m----1.14--7.18-0.08-0.080.01120.07050.0521--2.79---37.38---40.06-------717.76------0.00--379.22---96.04------
Terragen Holdings Ltd2.60m-2.53m6.27m----0.9179--2.41-0.0099-0.00990.01010.01850.33640.575811.93---32.71-43.86-39.59-50.1196.6187.96-97.24-173.815.79-347.500.0587--13.6731.2240.19---12.30--
Vectus Biosystems Ltd86.39k-2.49m6.92m----2.92--80.07-0.0467-0.04670.00160.04450.0191-------54.95-96.22-68.14-691.17-----2,880.80-27,693.78---439.760.00--69,287.5097.8713.64------
Neuroscientific Biopharmaceuticals Ltd3.94m761.17k7.09m--9.071.868.521.800.00540.00540.02730.02641.02--76.13--19.64-55.7223.29-60.89----19.34-301.54--54.640.00--7,292.97179.9789.76------
Epsilon Healthcare Ltd7.21m-5.93m7.21m----0.7868--0.9994-0.0198-0.01980.02410.03050.383917.942.73---31.54-35.68-46.30-41.1137.9926.88-82.17-197.560.5237-9.280.2329--29.3630.99-43.77--8.14--
Island Pharmaceuticals Ltd10.28k-2.37m7.67m----9.60--746.49-0.026-0.0260.00010.0070.0038--0.0318---88.77---134.02-------23,100.68------0.4433-------8.58------
Anatara Lifesciences Ltd0.00-1.75m8.98m----6.22-----0.014-0.0140.000.00760.00-------103.15-59.64-115.72-66.52-------1,927.05----0.00------20.10---40.49--
Avecho Biotechnology Ltd473.55k-3.44m9.51m29.00--1.49--20.08-0.0016-0.00160.00020.0020.08882.070.5132---64.45-47.08-75.73-55.25-9.2578.67-725.70-156.438.19--0.0267---58.07-19.42-46.71------
Calmer Co International Ltd2.46m-4.50m9.67m--------3.93-0.0091-0.00910.0042-0.00050.6551.349.62---119.81-139.15-231.33-198.5536.0330.26-182.94-388.810.482-9.361.22---13.00239.4311.40------
Nyrada Inc3.08m-4.98m10.23m----1.94--3.32-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Bioxyne Ltd8.65m-14.17m10.23m16.00--3.28--1.18-0.0074-0.00740.00440.00151.836.1210.50---302.23-22.07-418.10-28.5038.3045.13-165.04-39.691.50--0.00--1,013.0520.97-292.69---19.86--
Data as of May 28 2024. Currency figures normalised to Vectus Biosystems Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.